anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During the 1990-91 Gulf War (GW), military personnel were exposed to numerous chemical and environmental agents during deployment including spraying of pesticides, petroleum combustion products, and nerve gas. Exposure to these chemical and environmental agents can damage cell function and more specifically, mitochondrial function, which negatively affects energy production and can lead to oxidative stress and neuroinflammation. Animal models using similar exposures have documented this in the central nervous system (CNS) compartment. This disruption in mitochondrial function and energy production is likely tied to resulting symptoms of Gulf War Illness (GWI) including fatigue, headaches, joint and muscle pain, gastrointestinal and sleep disturbances, neurologic and neuropsychological symptoms, respiratory issues, and cardiovascular problems.

The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) plans to evaluate N-Acetyl Cysteine (NAC) as a promising approach to help the CNS recover from chronic oxidative stress and depletion of antioxidants. The Congressionally Directed Medical Research Program's (CDMRP's) two Gulf War Illness Consortiums (GWICs) and others have added to the growing evidence of the role of CNS oxidative stress and neuroinflammation in symptoms of GWI, yet there is little definitive work on the delivery of antioxidants to the CNS environment. In this mechanistic study, we aim to determine if NAC has the ability to target mitochondrial dysfunction and reverse oxidative stress in the CNS. Based on our early experiences with antioxidants in GWI and other complex disease states along with the proven record of NAC in reducing glutathione (GSH) deficits, it is possible that this antioxidant will help to restore mitochondrial function and provide a more targeted approach to improve outcomes in Veterans with GWI.
PURPOSE:To obtain an antiviral substance, consisting essentially of a glucide, protein, inorganic substance and modified water-soluble lignin prepared by extraction of a mycelial culture of a basidiomycete and having ultrahigh safety. CONSTITUTION:Mycelia of a basidiomycete (preferably SHIITAKE mushroom) are cultured in a culture medium containing a vegetable fiber ingredient (preferably bagasse) and the resultant culture is autolyzed. Warm water at >=40 deg.C or hot water is then poured thereinto to extract active ingredients. An alcohol is subsequently added to the resultant extract solution to collect a fraction soluble in 37.5% alcohol concentration and insoluble in 50% concentration thereof. The resultant fraction is then dissolved in a phosphoric acid buffer (pH7.2) containing 1 M ammonium sulfate and chromatographed with Phenyl- Sepharose(R). A fraction passing therethrough without adsorption and a fraction eluted with the phosphoric acid buffer solution are subsequently separated to afford the objective antiviral substance, having 10000-1500000 molecular weight and containing 12-20% glucide, 2-5% proteins, 70-85% modified water-soluble lignin and P, S, Mg, Ca, K and Na as inorganic ingredients as a fraction eluted with 75% ethylene glycol.
FIELD: medicine, endocrinology. SUBSTANCE: invention proposes method of infusion administration of medicinal agents in patients with diabetes mellitus involving preliminary assay of plasma osmotic pressure. In the case of hypo-, normo- or hyper- -osmotic values of plasma solutions of medicinal agents for infusion administration are prepared as hyper-, normo- or hypo-osmotic, respectively. For reinforcing hypo- or hyper- -osmocity of plasma solutions are prepared as hypo- or hyper-osmotic, respectively. EFFECT: enhanced safety and effectiveness of infusion therapy. 3 cl
A hard tissue repairing material includes zirconia as a base material. A surface of the base material has a hydrophilic group. The hydrophilic group is bonded to zirconium atom in the base material. The base material may contain at least an ionic component that is selected from a group consisting of calcium ion, sodium ion, potassium ion, and phosphate ions within the surface. A hard tissue repairing material may include zirconia as a base material and a layer of a main component of an apatite. The layer of the apatite may be formed on a hydrophilic group bonded to zirconium atom in the base material.
PURPOSE: To study the biological relationship between congenital lung malformations (CLMs) and malignancy.
METHODS: Biopsies of 12 CPAMs, 6 intralobar sequestrations and 2 extralobar sequestrations were analyzed through whole-genome sequencing. Blood samples from 10 patients were used to confirm or exclude somatic mosaicism. Putative somatic Single Nucleotide Variants (SNVs) were called for each malformed sample with a Panel of Normals built with control DNA samples extracted from blood. The variants were subsequently confirmed by Sanger sequencing and searched, whenever possible, in the blood samples of patients.
RESULTS: All CLMs but one presented a signature of genomic instability by means of multiple clusters of cells with gene mutations. Seven tumor transformation-related SNVs were detected in 6/20 congenital lung malformations. Four very rare in the general population SNVs were found in a region previously linked to lung cancer in 5p15.33, upstream of TERT oncogene. Furthermore, we identified missense genetic variants, whose tumorigenic role is well known, in the RET, FANCA and MET genes.
CONCLUSIONS: Genomic instability in 95% of CLMs and genetic variants linked to tumor development in 30% of them, regardless of histopathology, are predisposing factors to malignancy, that combined with exposure to carcinogens, might trigger the development of malignancy and explain the association between CLMs and lung cancer.
The safety and efficacy of caspofungin were evaluated in pediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.

The first study, which enrolled 82 patients between 2 to 17 years of age, was a randomized, double-blind study comparing caspofungin (50 mg/m 2IV once daily following a 70-mg/m 2loading dose on Day 1 [not to exceed 70 mg daily]) to AmBisome (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on AmBisome) as empirical therapy in pediatric patients with persistent fever and neutropenia. The study design and criteria for efficacy assessment were similar to the study in adult patients [see Clinical Studies (14.1)]. Patients were stratified based on risk category (high-risk patients had undergone allogeneic stem cell transplantation or had relapsed acute leukemia). Twenty-seven percent of patients in both treatment groups were high risk. Favorable overall response rates of pediatric patients with persistent fever and neutropenia are presented in Table 15. 

The second study was a prospective, open-label, non-comparative study estimating the safety and efficacy of caspofungin in pediatric patients (ages 3 months to 17 years) with candidemia and other Candidainfections, esophageal candidiasis, and invasive aspergillosis (as salvage therapy). The study employed diagnostic criteria which were based on established EORTC/MSG criteria of proven or probable infection; these criteria were similar to those criteria employed in the adult studies for these various indications. Similarly, the efficacy time points and endpoints used in this study were similar to those employed in the corresponding adult studies [see Clinical Studies (14.2, 14.3, and 14.4)]. All patients received caspofungin at 50 mg/m 2IV once daily following a 70-mg/m 2loading dose on Day 1 (not to exceed 70 mg daily). Among the 49 enrolled patients who received caspofungin, 48 were included in the efficacy analysis (one patient excluded due to not having a baseline Aspergillusor Candidainfection). Of these 48 patients, 37 had candidemia or other Candidainfections, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis. Most candidemia and other Candidainfections were caused by C. albicans(35%), followed by C. parapsilosis(22%), C. tropicalis(14%), and C. glabrata(11%). The favorable response rate, by indication, at the end of caspofungin therapy was as follows: 30/37 (81%) in candidemia or other Candidainfections, 5/10 (50%) in invasive aspergillosis, and 1/1 in esophageal candidiasis.
In 2023, Africa experienced 180 public health emergencies, of which 90% were infectious diseases and 75% were related to zoonotic diseases. Testing capacity for epidemic-prone diseases is essential to enable rapid and accurate identification of causative agents, and for action to prevent disease spread. Moreover, testing is pivotal in monitoring disease transmission, evaluating public health interventions and informing targeted resource allocation during outbreaks. An online, self-assessment survey was conducted in African Union Member States to identify major challenges in testing for epidemic-prone diseases. The survey assessed current capacity for diagnosing priority epidemic-prone diseases at different laboratory levels. It explored challenges in establishing and maintaining testing capacity to improve outbreak response and mitigate public health impact. Survey data analysed diagnostic capacity for priority infectious diseases, diagnostic technologies in use, existing surveillance programmes and challenges limiting diagnostic capacity, by country. The survey result from 15 Member States who responded to the survey, showed high variability in testing capacity and technologies across countries and diverse factors limiting testing capacity for certain priority diseases like dengue and Crimean-Congo haemorrhagic fever. At the same time diagnostic capacity is better for coronavirus disease 2019 (COVID-19), polio, and measles due to previous investments. Unfortunately, many countries are not utilizing multiplex testing, despite its potential to improve diagnostic access. The challenges of limited laboratory capacity for testing future outbreaks are indeed significant. Recent disease outbreaks in Africa have underscored the urgent need to strengthen diagnostic capacity and introduce cost-effective technologies. Small sample sizes and differing disease prioritisation within each country limited the analysis. These findings suggest the benefits of evaluating laboratory testing capacity for epidemic-prone diseases and highlight the importance of effectively addressing challenges to detect diseases and prevent future pandemics.
Disclosed herein are compositions and compounds that combine an inhibitor of  5 -lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an agent that itself produces NO in the mammal. Further disclosed herein are strategies for synthesizing such compounds, and methods for testing whether the combination compounds and compositions provide a desired benefit. Also disclosed herein are pharmaceutical compositions and formulations that combine a FLAP inhibitor and an NO modulator. Further described herein are methods for using such compositions and compounds for the treatment of diseases, conditions, and disorders in a mammal, including a human. Such treatment methods include the separate administration of a FLAP inhibitor and a NO modulator to the mammal, and the simultaneous administration of a FLAP inhibitor and a NO modulator to the mammal.
OBJECTIVE: The precise indications for employing the anterior component separation technique (ACST) and the Transversus Abdominis Release (TAR) in abdominal wall reconstruction (AWR) remain uncertain, despite the undeniable value of both techniques. The aim of this study was to analyze the anterior fascial closure rate, postoperative wound morbidity, and hernia recurrence rate for both procedures according to the algorithm used for complex AWR.
METHODS: A retrospective analysis of prospectively collected data was carried out. Patients undergoing AWR for midline incisional hernias using either open or endoscopic ACST (E-ACST) or TAR between March 2013 and August 2022 were included. Patients with lateral hernia components were excluded. The surgical technique was depending on the pre- and intraoperative findings regarding hernia width and on the estimated traction to achieve anterior fascial closure (see algorithm). Initially, intermediate hernia defects ranging from approximately 10-14 cm in width were repaired using E-ACST. However, as the study advanced, TAR became the preferred method for addressing these types of defects. Open ACST was consistently employed for defects wider than 14-15 cm throughout the entire study duration. Outcomes of interest were anterior fascial closure, surgical site occurrences, and hernia recurrence rate. Follow-up was performed at 1 month, 1 year, and 2 years.
RESULTS: A total of 119 patients underwent AWR with CST: 63 patients (52.9%) were included in the ACST group and 56 patients (47.1%) in the TAR group. No significant differences were observed in patient and hernia characteristics. The use of botulinum toxin A (BTA) injection and preoperative progressive pneumoperitoneum (PPP) was more frequently used in the ACST group (BTA 19.0%, PPP 15.9% versus BTA 5.4%, PPP 1.8% for TAR patients). Anterior fascial closure was achieved in 95.2% of the ACST group and 98.2% of the TAR group (p = 0.369). The TAR group demonstrated a significantly lower SSO rate at one month (44.3% versus 14.3%, p < 0.001) and required fewer procedural interventions (SSO-PI) (31.1% versus 8.9%, p = 0.003). The recurrence rate at one year was low and there was no statistically significant difference between the two groups (ACST 1.8% vs TAR 4.5%, p = 0.422).
CONCLUSION: Following a proposed algorithm, the anterior fascial closure rate was high and similar for both techniques. As postoperative wound morbidity is significantly increased after ACST, our findings support recommending TAR for defects up to 14 cm in width, while favoring open ACST for larger defects.
1,141,837. Setting hair. REALISTIC CO. 3 May, 1966, No. 19333/66. Heading D1P. Hair is permanently set by a process which comprises treating it first with a solution of a reducing agent for keratin and then with an aqueous solution of an oxidizing agent for reduced keratin which contains at least 18% by weight of a water soluble non-toxic salt of magnesium, aluminium or calcium. The solution of the reducing agent may be an aqueous solution contaimng 7% by weight of thioglycollic acid and sufficient ammonia to provide an excess and give a pH of 9.4. The oxidising agent may be an ammonium, alkali metal or alkaline earth metalbromate, iodate or periodate, suitable agents being sodium bromate, sodium periodate or magnesium or calcium bromate or iodate, aluminium bromate or iodate, hydrogen peroxide or urea peroxide and the salt may be magnesium sulphate, aluminium sulphate, calcium acetate or calcium chlorate. The solution of the oxidizing agent may also contain sodium lauryl ether sulphate, sodium alkyl phenoxyether sulphonate, sulphuric acid or boric acid.
PURPOSE:To obtain a fluorine-contained monomer useful as artificial denture base, etc., having one double bond in the molecule, by reacting a fluorine-contained multiple telomer having one hydroxyl group at the end of a molecular chain and a specific molecular weight with (meth)acrylic acid chloride. CONSTITUTION:Two or more fluorine-contained monomers (e.g., vinylidene fluoride, vinyl fluoride, etc.) and any primary tertiary alcohol as a telogen are subjected to telomerization in an alcohol, to give a fluorine-contained multiple telomer having <=1,500mol.wt. and one hydroxyl group at the end of a molecular chain. The telomer is esterified with (meth)acrylic acid chloride in a solvent such as carbon tetrachloride, etc., to give the desired substance. USE:An artificial denture base, weather-resistant paint, etc.
There is a general suspicion that stress and stress-related psychological disorders is growing in highschool students in Sweden. Mindfulness is a well researched therapeutical method for treating stress-related disorders. This study will first collect data on stress-related psychological symptoms by several well-validated surveys. The surveys will be made twice with 8 weeks in between to examine variability. After the second survey the population of highschool students will be randomly assigned to web-based mindfulness intervention, music relaxation intervention or control group. A third survey will be conducted after eight weeks of intervention and before and after an external stressor.
Before the reflexology application, a personal information form was applied to the patients who had abdominal surgery. As a pre-test, satisfaction levels in terms of pain and nursing were evaluated. Then, vital signs (systolic blood pressure, diastolic blood pressure, pulse, respiration and saturation) were measured. Foot warming movements were started and then the warming movements were terminated by applying pressure to the solar plexus area of the left foot. Then in order; Reflexology was applied to the brain, lymphatic system, blood pressure area, lung, adrenal gland, thyroid, diaphragm, stomach and joint areas. Afterwards, relaxation movements were made for the foot, pressure was applied to the solar plexus and the reflexology application was completed within 30 minutes. Immediately after the application, vital signs were re-measured as a post-test, and the numerical pain scale and care satisfaction scale were applied again.
Dark chocolate and other cocoa products contain antioxidants including the polyphenol epicatechin that have beneficial effects on vascular function. Oral consumption of dark chocolate lowers blood pressure in elderly subjects with isolated systolic hypertension while drinking cocoa acutely improves flow-mediated vasodilation in subjects with cardiovascular risk factors. Work from our lab and elsewhere has shown that regulation of hemodynamic and metabolic homeostasis are coupled such that subjects with essential hypertension are also insulin resistant. Therefore, we hypothesize that cocoa consumption will improve both blood pressure and insulin sensitivity in subjects with essential hypertension. To test this hypothesis, we will conduct a randomized double-blind, crossover study in subjects with essential hypertension to evaluate the effects of cocoa versus placebo on blood pressure, insulin sensitivity, and insulin-mediated capillary recruitment in skeletal muscle. After a 7 day cocoa-free run-in period, subjects will be randomized to receive 15 consecutive daily doses of either cocoa drink (150 ml twice a day with a total of 900 mg of polyphenols and 237 kcal) or polyphenol poor placebo drink (150 ml twice a day with a total of 36 mg of polyphenols and 234 kcal). After the 15 day treatment period, the subjects will enter a 1 week cocoa-free washout period followed by cross-over to the other treatment. Subjects will be counseled to maintain an isocaloric diet during the study. Blood pressure, insulin sensitivity, and insulin-mediated capillary recruitment will be assessed in each subject after the run-in period, after 15 days of treatment, and after completion of the cross-over. Blood pressure will also be measured every Monday, Wednesday, and Friday for the duration of the study. Insulin sensitivity will be measured using the hyperinsulinemic euglycemic glucose clamp technique. Insulin-stimulated capillary recruitment in forearm skeletal muscle will be measured by ultrasound with "microbubble" contrast during the glucose clamp studies. Peak and trough plasma epicatechin levels will be measured prior to each glucose clamp study using an HPLC assay. This study will determine if short-term oral administration of cocoa is effective at lowering blood pressure, improving insulin sensitivity, and restoring vascular function in subjects with essential hypertension. This is highly relevant to major public health problems such as diabetes, obesity, hypertension, and cardiovascular diseases where insulin resistance and vascular dysfunction are important pathophysiological components.
Caffeine supplementation has been studied in several sports modalities with the objective of investigating its repercussions on athletes' physical performance. Caffeine may lead to an obstruction of adenosine receptors (A1 and A2) and increase the activity of the Autonomic Nervous System (ANS) by releasing catecholamines in plasma, inducing tachycardia and elevating blood pressure. Such modulation of nervous system activity can be traced by assessing heart rate variability (HRV). HRV is one of the most practical methods to analyze the physiological functioning of ANS, both in pathological conditions of the individual and in the induction of other variables, being a noninvasive measure of cardiac autonomic modulation markers that analyzes the peak-R intervals a peak-R (RRI) of consecutive heartbeat. The objective of this study was to evaluate the variability of the heart rate of exercise physicists with and without caffeine intake. Practitioners of resisted physical exercise, specifically bodybuilding, who are young adults between the ages of 18 and 30 will participate in the study. To define the sample size, a sample calculation was performed based considering as variable the RMSSD index (square root of the square mean of the differences between the adjacent normal iRRs). The significant difference magnitude assumed was 12 ms, considering a standard deviation of 16.2 ms, with alpha risk of 5% and beta of 80%. A minimum of 14 subjects per group were required in the survey. A total of 32 subjects will participate in the research, being these divided and allocated in different groups. Sampling will be of the intentional kind.

The expected benefits with the result of this research are to instigate the creation of new lines of research in this context, being able to intervene in a more effective way in practitioners of physical exercise of strength, with the possibility of prevention to the autonomic alterations that are associated with the consumption of stimulant supplements, such as caffeine, and its consequences on the cardiovascular system.
The invention belongs to the biotechnology and cell engineering field and relates to the establishment of two hybridoma cell lines secreting anti-oophoroma anti-idiotype monoclonal antibodies. The invention is mainly technically characterized by taking a murine anti-oophoroma anti-idiotype monoclonal antibody as an immunogen to immunize a Balb/C mouse and using the hybridoma technology to obtain the hybridoma cell lines stably secreting anti-oophoroma anti-idiotype monoclonal antibodies through fusion, screening and repeated cloning. The two hybridoma cell lines which are respectively named as OVCAMab3D12 and OVCAMab32F2 are preserved by the common microorganism center of China Committee of Culture Collection for Microorganisms with respective collection numbers of CGMCCNo.2144 and CGMCCNo.2145. The invention also discloses monoclonal antibodies 6B11Ab3(IgM) and 6B11Ab3(IgG) respectively through the two hybridoma cell lines. The antibodies can be applicable to an ELISA kit capable of detecting oophoroma associated antigen for early diagnosis of oophoroma. Simultaneously the antibodies can be used for the development of oophoroma curative medicines, particularly targeted therapeutic medicines, and for the therapy of oophoroma.
This is a multicentric, prospective study . Patients will be referred to one of seven surgeons specialized in the surgical management of gastric cancer. Patients will undergo DL, with intravenous (IV) injection of 0.25 mg/kg of free ICG at the start of the surgery. DL will be first performed without fluorescence imaging in the standard fashion, with identification of potential PM. A first peritoneal cancer index (PCI) score will be calculated. Fluorescence imaging will then be performed, and correlation with previously identified lesions will be assessed and a second PCI score (with ICG) will be calculated. Biopsies will be performed to confirm the metastatic status of the lesions. Any suspicion for additional lesions visualized only under fluorescence imaging will be biopsied as well. Peritoneal fluid cytology will be performed at the beginning of the surgery.